Valutazione della risposta alla terapia in un paziente con amiloidosi AL e basse concentrazioni della catena leggera libera monoclonale

Translated title of the contribution: Evaluation of response to treatment in a patient with light chain amyloidosis and low free light chain burden.

Marco Basset, Paolo Milani, Francesca Russo, Mario Nuvolone, Francesca Lavatelli, Tiziana Bosoni, Laura Pirolini, Li Bergolis Filomena, Andrea Foli, Riccardo Albertini, Giovanni Palladini, Giampaolo Merlini

Research output: Contribution to journalArticle

Abstract

In patients with light chain (AL) amyloidosis, reduction of amyloidogenic circulating free light chain (FLC) concentration translates in improvement of organ dysfunction and is associated with an increase in overall survival. Validated criteria for hematologic response to therapy are based on FLC quantification. However, patients with a difference between involved and uninvolved FLC (dFLC) &50 mg/L are not evaluable for hematologic response. Here we report the case of a 69 year old man with AL (λ) amyloidosis with renal involvement, presenting a low-FLC burden (dFLC 41 mg/L) at diagnosis. After two lines of treatment, a profound reduction of amyloidogenic FLC (dFLC 0 mg/L) was associated with an improvement of organ dysfunction. This case emphasizes the role of FLC assessment in the monitoring also of patients with a low-dFLC burden.

Translated title of the contributionEvaluation of response to treatment in a patient with light chain amyloidosis and low free light chain burden.
Original languageItalian
Pages (from-to)E4-E6
JournalBiochimica Clinica
Volume43
Issue number1
DOIs
Publication statusPublished - Jan 1 2019

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Medical Laboratory Technology
  • Biochemistry, medical

Fingerprint Dive into the research topics of 'Evaluation of response to treatment in a patient with light chain amyloidosis and low free light chain burden.'. Together they form a unique fingerprint.

  • Cite this